Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study

Goodwin, Scott R.; Reeds, Dominic N.; Royal, Michael; Struthers, Heidi; Laciny, Erin; Yarasheski, Kevin E.

doi:10.1210/jc.2012-3532

Cited by 36 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our participants, SDF‐1α levels were rather decreased by vildagliptin (Table ). In the case of non‐diabetic HIV‐positive patients, sitagliptin treatment up to 24 weeks also decreased serum SDF‐1a levels compared with a placebo. More recently, Aso et al .…”

Section: Discussionmentioning

confidence: 96%

Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

Park

Kwak

Cho

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionDipeptidyl peptidase‐4 inhibitors might have pleiotropic protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore, we compared various CVD risk factors between vildagliptin and glimepiride.Materials and MethodsWe carried out a randomized, prospective and crossover trial. A total of 16 patients with type 2 diabetes whose glycated hemoglobin was >7% were randomized to add vildagliptin or glimepiride. After 12‐week treatment, each drug was replaced with the other for another 12 weeks. Before and after each treatment, glucose homeostasis and CVD risk factors were assessed, and the continuous glucose monitoring system was applied to calculate glycemic variability.ResultsThe mean age of the participants was 60 years, 31% were men, body mass index 25.5 kg/m2 and HbA1c 8.41%. Both vildagliptin and glimepiride significantly decreased glycated hemoglobin and glycemic variability indices. Despite the improved glucose homeostasis, favorable change of CVD markers was not prominent in both the arms, along with significant weight gain. Only plasma stromal cell‐derived factor (SDF)‐1α decreased by 30% in the vildagliptin arm. According to regression analyses, the reduction of SDF‐1α was independently associated with vildagliptin usage and serum interleukin‐6 changes, but white blood cells were not related with the SDF‐1α changes.ConclusionCompared with glimepiride, vildagliptin arrestingly decreased plasma SDF‐1α, and its clinical implications should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 96%

Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

Park

Kwak

Cho

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…Previously, we found that sitagliptin (100 mg/d, 16 -24 wk) did not adversely affect virological or immune status in cART-treated HIVϩ adults with normal glucose tolerance (21). Whether sitagliptin reduces inflammation and immune cell activation in HIVϩ adults with impaired glucose tolerance (IGT) is unknown.…”

mentioning

confidence: 99%

Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance

Best

Struthers

Laciny

et al. 2015

The Journal of Clinical Endocrinology & Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…Whereas the majority of successful antipsoriatic medications are immunosuppressive, none of the hypoglycemic agents show evidence of suppression of the immune system [78][79][80][81] . These medications are frequently used in the diabetic population without complication, and the side effects are well tolerated.…”

Section: Resultsmentioning

confidence: 99%

“…An earlier consultation from endocrinology may be beneficial. Hypoglycemic agents are commonly used, safe, well tolerated, and are unlikely to be immunosuppressive [78][79][80][81] . For patients in which immunosuppression is contraindicated, off-label usage of hypoglycemic agents may be warranted to control severe psoriasis and improve quality of life while avoiding the toxic effects of other systemic therapies.…”

Section: Resultsmentioning

confidence: 99%

Glycemic Control in the Treatment of Psoriasis

Ip¹,

Kirchhof

2017

Dermatology

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, thiazolidinediones and biguanides, exert beneficial effects in psoriasis. In this review, we summarize the growing evidence supporting the therapeutic role of hypoglycemic agents in psoriasis and discuss the potential underlying mechanisms. We suggest that dermatologists consider the use of hypoglycemic agents in psoriasis especially in cases with coexisting diabetes and in cases in which immunosuppression is contraindicated. Earlier referral to endocrinology in patients with concomitant diabetes may be appropriate.

show abstract

Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study

Cited by 36 publications

References 37 publications

Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance

Glycemic Control in the Treatment of Psoriasis

Contact Info

Product

Resources

About